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Abstract
Background: Testosterone deficiency in patients with heart failure (HF) is associated with decreased exercise capacity 
and mortality; however, its impact on hospital readmission rate is uncertain. Furthermore, the relationship between 
testosterone deficiency and sympathetic activation is unknown.
Objective: We investigated the role of testosterone level on hospital readmission and mortality rates as well as 
sympathetic nerve activity in patients with HF.
Methods: Total testosterone (TT) and free testosterone (FT) were measured in 110 hospitalized male patients with a left 
ventricular ejection fraction < 45% and New York Heart Association classification IV. The patients were placed into low 
testosterone (LT; n = 66) and normal testosterone (NT; n = 44) groups. Hypogonadism was defined as TT < 300 ng/dL 
and FT < 131 pmol/L. Muscle sympathetic nerve activity (MSNA) was recorded by microneurography in a subpopulation 
of 27 patients.
Results: Length of hospital stay was longer in the LT group compared to in the NT group (37 ± 4 vs. 25 ± 4 days; 
p = 0.008). Similarly, the cumulative hazard of readmission within 1 year was greater in the LT group compared to in the 
NT group (44% vs. 22%, p = 0.001). In the single‑predictor analysis, TT (hazard ratio [HR], 2.77; 95% confidence interval 
[CI], 1.58–4.85; p = 0.02) predicted hospital readmission within 90 days. In addition, TT (HR, 4.65; 95% CI, 2.67–8.10; 
p = 0.009) and readmission within 90 days (HR, 3.27; 95% CI, 1.23–8.69; p = 0.02) predicted increased mortality. 
Neurohumoral activation, as estimated by MSNA, was significantly higher in the LT group compared to in the NT group 
(65 ± 3 vs. 51 ± 4 bursts/100 heart beats; p < 0.001).
Conclusion: These results support the concept that LT is an independent risk factor for hospital readmission within 
90 days and increased mortality in patients with HF. Furthermore, increased MSNA was observed in patients with LT. 
(Arq Bras Cardiol. 2015; 105(3):256‑264)
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Introduction
Symptoms attributable to heart failure (HF), including 
dyspnea, fatigue, and muscle weakness, lead to > 1 million 
hospitalizations per year in the United States and Brazil1, 
with readmission rates within 90 days approaching 50%2,3. 
Although the importance of HF-related costs as a major 
contributor to the healthcare spending crisis has been 
recognized, more than 20 pharmacological trials worldwide 
focusing on mortality as an endpoint have been negative2. 
As a large proportion of patients with HF would trade 
increased length of life for increased quality of life4, which 
is directly linked to exercise capacity5, it may be reasonable 
to refocus therapeutic targets in patients with HF to improve 
exercise and functional capacity.
Testosterone deficiency is recognized in a large number 
of male patients with advanced HF and is correlated with 
decreased functional class, exercise capacity, and muscle 
strength6-8, and in some studies9, but not all10, testosterone 
deficiency is associated with increased mortal i ty. 
Testosterone therapy is recommended for men with a 
testosterone deficiency and symptoms of hypogonadism 
to increase exercise capacity. Testosterone therapy is 
associated with increased exercise tolerance in patients 
with HF compared with placebo, which is not explained 
by impaired cardiac function8,11-14.
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Considering that cardiac function does not improve 
following testosterone therapy, and the growing acceptance 
of the “muscle hypothesis,” which argues that exercise 
limitations in patients with chronic HF are focused on 
the periphery, including abnormalities in the reflexes 
activated during exercise15,16, testosterone therapy may have 
beneficial effects on the neurohumoral state in patients with 
HF. Indeed, decreased baroreceptor sensitivity and heart 
rate variability (HRV) have been reported in patients with 
a testosterone deficiency17.
The purpose of this study was to test the hypothesis 
that testosterone deficiency is associated with an increased 
risk for subsequent re-hospitalization within 30, 60, and 
90 days. Additionally, we evaluated mortality rate in 
hospitalized male patients with HF due to decompensated 
HF. Moreover, we tested the hypothesis that patients with 
HF and testosterone deficiency have greater neurohumoral 
activation; i.e., increased levels of muscle sympathetic 
nerve activity (MSNA) compared to in patients with HF and 
normal testosterone (NT) levels to begin to understand the 
mechanisms underlying this potential inverse relationship.
Methods
Study Population
We prospectively evaluated 110 consecutive hospitalized 
male patients with HF who agreed to participate. Those who 
met the study inclusion criteria had acute decompensated 
HF and were functional class IV. Other study criteria were as 
follows: 1) age between 18 and 65 years old, 2) HF diagnosis 
> 6 months, and 3) left ventricular ejection fraction 
(LVEF) < 45%. Exclusion criteria were as follows: 1) history 
of coronary revascularization or myocardial infarction 
< 6 months before the study, 2) any hormonal treatment, 
including exogenous testosterone therapy, before or during 
the protocol, 3) advanced kidney disease, liver disease, or 
diabetes, 4) obesity (body mass index > 30 kg/m2), and 
5) prostatic cancer or benign prostatic hyperplasia with or 
without anti-androgen therapy (finasteride, doxazosin, or 
tamsulosin). Written informed consent was obtained from 
all participants before the study; this study was approved 
by the local ethics committee and is registered at Clinical 
Trials (NCT01852994).
Laboratory Measurements
For all patients, blood samples for androgen testing 
were collected on the morning of hospital admission. 
If the patient was admitted during the afternoon or at night, 
androgen testing was done the next morning. Serum levels 
of total testosterone (normal range, 300–965 ng/dL; 
intra‑assay coefficient of variation [CV] ≤ 7.5% and 
inter‑assay CV ≤ 5.4%), sex hormone‑binding globulin 
(SHBG; normal range, 12–75 nmol/L; intra‑assay CV ≤ 2.3% 
and inter‑assay CV ≤ 6%) were determined according to 
standard laboratory techniques in the clinical laboratory at 
the Hospital da Clínicas, University of Sao Paulo Medical 
School. Free testosterone (normal range, 131–640 pmol/L) 
was calculated using SHBG and total testosterone in the 
formula proposed by Vermeulen et al18. Hypogonadism was 
defined in the laboratory as total testosterone < 300 ng/dL 
and free testosterone < 131 pmol/L19,20. B-type natriuretic 
peptide (BNP), C-reactive protein (CRP), hemoglobin, blood 
urea nitrogen (BUN), creatinine, sodium, potassium, and 
fasting blood glucose levels were also measured on the 
morning of hospital admission. Estimated glomerular filtration 
rate (eGFR) was calculated using the Modification of Diet 
in Renal Disease equation recommended by the National 
Kidney Disease Education Program.
Muscle sympathetic nerve activity
Patients were stabilized on oral medication therapy 
and underwent microneurographic recording of MSNA. 
Microneurography of the peroneal nerve is a safe, precise, 
direct technique to record SNA directed to muscle21. 
MSNA was recorded in a subpopulation of 27 patients 
during hospitalization. In brief, a tungsten microelectrode 
was placed on the peroneal nerve, and a sympathetic 
neurogram was recorded. Nerve signals were amplified by 
50,000–100,000 and band-pass filtered (700–2,000 Hz). 
Nerve activity for recording and analysis was rectified and 
integrated (time constant, 0.1 s) to obtain a mean voltage 
display. Muscle sympathetic bursts were identified by visual 
inspection (M.R.S.), who was blinded to the study protocol. 
MSNA was expressed as burst frequency (bursts/min) and 
burst incidence (bursts/100 heart beats [HB]).
Echocardiography
LVEF was evaluated (Teicholz) using two-dimensional 
imaging according to standard methods22.
Follow-up
All patients were followed up after discharge by a dedicated 
research nurse through electronic health records and by 
periodic phone calls.
Statistical Analysis
The Kolmogorov–Smirnov test was used to verify that 
all data were normally distributed. Student’s t-test and the 
Mann–Whitney U-test were used to compare parametric 
and non-parametric data, respectively. The chi-square (X2) 
test was used to analyze medications and the HF etiology 
data. The Cox proportional hazards model was used to 
test the associations between the analyzed variables and 
endpoints (readmissions within 30, 60, and 90 days and 
mortality). We included length of stay after the first hospital 
admission, age, LVEF, coronary artery disease (CAD) or 
no CAD, BNP, CRP, hemoglobin, urea, creatinine, eGFR, 
sodium, potassium, fasting blood glucose, total testosterone, 
free testosterone, and SHBG in the single-predictor analysis 
for readmission. We included the same variables as above 
in the single-predictor analysis for mortality, as well as 
readmission within 30, 60, and 90 days of discharge. 
Forward and backward stepwise multivariate model 
analyses (p = 0.10) were conducted to assess which factors 
independently predicted readmission and mortality in the 
single-predictor analysis. Survival was evaluated using 
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a Kaplan–Meier analysis with 95% confidence intervals 
(CIs) between total testosterone and mortality within 
1 year. Furthermore, a Kaplan–Meier analysis was used 
to evaluate the relationship between total testosterone 
level and readmission within 1 year. The Cox–Mantel 
log-rank test was used to evaluate differences in survival 
and readmission rates. A p value < 0.05 was considered 
statistically significant.
Results
Sixty-six patients were classified with low testosterone (LT), 
and 44 had NT during hospitalization. The characteristics of 
the LT and NT groups are compared in Table 1. The LT and 
NT groups were not different in age, etiology of HF, LVEF, or 
medications used, but BNP, CRP, BUN, creatinine, and fasting 
blood glucose levels were significantly higher in the LT group 
than those in the NT group. In contrast, hemoglobin, eGFR, 
sodium, and total and free testosterone levels were significantly 
lower in the LT group than those in the NT group.
Length of hospital stay during the first admission
The LT group had a significantly longer hospital stay than 
the NT group (37 ± 4 vs. 25 ± 4 days, respectively) (Figure 1; 
p = 0.008). This relationship persisted even when outliers 
(values > 2 standard deviations) were excluded. Six patients 
died in the LT group and two died in the NT group during 
this first admission.
Readmissions after the first admission
The medications at discharge were not different between 
the LT and NT groups (Table 2). The median times for the 
first readmission were 94 days (LT group) and 137 days 
(NT group). Readmission rate was greater in the LT compared 
to in the NT group when measured at 30, 60, and 90 days. 
However, readmission rates within 30 and 60 days were 
not related to any variable tested in the Cox regression. 
Total testosterone was the only variable related to this poor 
outcome in the single-predictor analysis for readmission 
within 90 days (hazard ratio [HR], 2.77; 95% CI, 1.58–4.85, 
p = 0.02; Table 3). All variables related to readmission within 
90 days in the single-predictor analysis were included in 
the multivariate Cox proportional hazard model analyses. 
The final model after forward and backward stepwise analyses 
consisted of only total testosterone (forward: HR, 2.49; 
95% CI, 1.33–4.65; p = 0.04 and backward: HR, 2.48; 
95% CI, 1.33–4.65; p = 0.004) for readmission within 90 days. 
In addition, the cumulative hazard for readmission was higher 
in the LT group compared to in the NT group (Figure 2; 
n = 102; p = 0.001) at the 1-year follow-up.
Mortality at the 1-year follow-up
Following first discharge, the LT group had significantly 
higher mortality compared than the NT group (Figure 3; 
n = 102; p = 0.001) at the 1-year follow-up: 24 patients in 
the LT group and seven in the NT group died within 1 year 
after hospital discharge. In the single-predictor analysis, total 
testosterone (HR, 4.65; 95% CI, 2.67–8.10; p = 0.009; 
Table 3) and readmission within 90 days (HR, 3.27; 
95% CI, 1.23-8.69; p = 0.02; Table 3) were predictors of 
mortality. All variables that were related to mortality in the 
single-predictor analysis were included in the multivariate 
Cox proportional hazard model analyses. The final model 
after the forward stepwise analysis included total testosterone 
(forward: HR, 3.86; 95% CI, 2.06–7.21; p < 0.001) 
and readmission within 90 days (forward: HR, 3.08; 
95% CI, 1.57–6.04; p = 0.001) for mortality. The backward 
stepwise analysis for mortality included total testosterone 
(HR, 3.86; 95% CI, 2.06–7.21; p < 0.0001), eGFR (HR, 0.97; 
95% CI, 0.95–0.9; p = 0.034), readmission within 90 days 
(HR, 2.39; 95% CI, 1.05–5.45; p = 0.038), and readmission 
within 60 days (HR, 2.96; 95% CI, 1.01–8.67; p = 0.047).
Muscle sympathetic nerve activity
MSNA was significantly higher in the LT group compared 
to in the NT group when calculated as bursts/100 HB, 
(65 ± 3 vs. 51 ± 4 bursts/100 HB, p < 0.001). MSNA tended 
to be higher in the LT group compared to in the NT group 
when calculated as bursts/min (47 ± 3 vs. 43 ± 4 bursts/min, 
p > 0.05), but was not statistically significant.
Discussion
Although testosterone deficiency is associated with heart 
disease and elevated mortality23, testosterone level is not 
commonly used in clinical practice to measure the severity 
and prognosis in patients with HF. Our findings extend the 
observation that LT is associated with an increased cardiac 
risk by demonstrating that LT is associated with increased 
mortality in a cohort with HF. Furthermore, deficiency 
in total testosterone was an independent risk factor for 
increased morbidity as evidenced by the increase in hospital 
readmissions within 90 days.
The stepwise analysis for mortality was strongly related 
to readmission within 90 days (forward) and readmission 
within 60 days (backward), as well as total testosterone and 
eGFR. One review reported that later hospital readmission 
(> 30 days) is associated with renal insufficiency and 
elevated BNP level2. Interestingly, we did not find an 
association between earlier readmission (within 30 days) 
and a testosterone deficiency in our patients. This result is 
consistent with the notion that a 30-day readmission may 
be related to poor social support and low socioeconomic 
status rather than to an increase in clinical comorbidities2. 
In fact, we found that a testosterone deficiency was 
associated with greater activation of the sympathetic 
nervous system, and increased sympathetic nerve activity 
is a risk factor for increased mortality in patients with 
HF24. The increased sympathetic activation may provide a 
potential mechanism, which will be discussed below.
Some studies have reported an inconsistent association 
between testosterone and mortality in patients with HF. 
Jankowska et al9 found that low total testosterone is associated 
with increased mortality. In contrast, Guder et al10 reported 
that LT is not an independent risk factor for decreased survival 
in patients with HF. These disparate findings can be explained 
by differences in the HF populations; the population studied 
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Table 1 – Physical, clinical, and hormonal characteristics of men with heart failure at the first admission
Variables Low Testosterone (n = 66) Normal Testosterone (n = 44) p value
Age, y 52 ± 1 51 ± 2 0.70
Weight, kg 72 ± 2 71 ± 2 0.52
Height, m 1.70 ± 0.01 1.69 ± 0.01 0.78
BMI, kg/m2 25 ± 1 24 ± 1 0.54
LVEF, % 25 ± 1 27 ± 1 0.24
TT, ng/dL 237 ± 11 652 ± 41 < 0.001
FT, pmol/L 124 ± 9 323 ± 21 < 0.001
SHBG, nmol/L 60 ± 3 73 ± 5 0.037
Etiology of HF 0.81
CAD 17 (26%) 9 (20%)
Non CAD 49 (74%) 35 (80%)
Chagasic 17 14
Hypertensive 3 3
Idiopathic 29 18
Treatment, N (%)
ACE-I/ARB 29 (44%) 24 (55%) 0.28
β-blockers 51 (77%) 26 (59%) 0.04
Diuretics 57 (86%) 33 (75%) 0.13
Digoxin 13 (20%) 10 (23%) 0.70
Statin 18 (27%) 8 (18%) 0.27
Aspirin 26 (39%) 11 (25%) 0.12
Biomarkers
BNP, pg/mL 1725 ± 153 804 ± 112 0.006
CRP, mg/L 35 ± 6 15 ± 3 0.007
BUN, mg/L 70 ± 4 56 ± 4 0.04
Creatinine, mg/L 1.66 ± 0.10 1.32 ± 0.05 0.02
Fasting glucose, mg/L 114 ± 3 94 ± 2 0.01
Hemoglobin, g/dL 12.30 ± 0.26 13.57 ± 0.30 0.007
GFR, mL·min-1·1.73 m-2 49 ± 2 55 ± 1 0.03
Sodium, mEq/L 135 ± 1 137 ± 0.4 0.04
Potassium, mEq/L 4.38 ± 0.07 4.51 ± 0.08 0.29
Six patients in the low testosterone group and two patients in the normal testosterone group died during the first admission and were excluded from subsequent 
analyses. BMI: Body mass index; LVEF: Left ventricular ejection fraction; TT: Total testosterone; FT: Free testosterone; SHBG: Sex hormone-binding globulin; 
CAD: Coronary artery disease; ACE-I/ARB: Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BNP: B-type natriuretic peptide; CRP: C-reactive 
protein; BUN: Blood urea nitrogen; GFR: Glomerular filtration rate.
by Guder et al10 included a large proportion (~50%) of patients 
with HF and preserved LVEF, unlike those in the study by 
Jankowska et al9 In addition, they speculated that their findings 
differed from those of Jankowska et al. because they included 
additional prognostic variables, such as medication use, 
inflammatory markers, and others. Importantly, the additional 
variables included by Guder et al10 as well as several others 
were included in our study, and LT remained an independent 
predictor of increased mortality in patients with advanced HF 
and systolic dysfunction in our study. 
We found that total testosterone, not free testosterone, 
was associated with poor outcomes. Total testosterone 
consists of free testosterone plus testosterone bound 
to SHBG and albumin; free testosterone is the active 
fraction. A meta-analysis reported that a decrease in total 
testosterone is associated with 35% and 25% increased risks 
of all-cause and cardiovascular disease mortality in men, 
respectively25. Another study on patients with HF showed 
that a deficiency in SHBG is associated with a higher risk of 
cardiac death26. In contrast, high levels of SHBG lead to a 
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lower bioavailability of free testosterone and has been linked 
to increased mortality in men when augmented by SHBG27. 
Although we found a significant difference in SHBG levels 
between the LT and NT groups, the result remained within 
the normal range in our laboratory (20.6-76.7 nmol/L). 
SHBG levels can be altered by non-cardiac medications, 
diet, and specific illnesses but the relative importance of 
these factors in our patients is not known.
Although a deficiency in androgens has been previously 
associated with increased morbidity, particularly a decrease 
in exercise capacity, our study is the first to examine 
Table 2 – Medications and daily dosages at discharge (first admission) in men with heart failure
Variables Low Testosterone (n = 60) Normal Testosterone (n = 42) p value
Treatment, N (%)
β-blocker 52 (87%) 39 (93%) NS
ACE-I/ARB 41 (68%) 36 (86%) NS
Spironolactone 25 (42%) 19 (45%) NS
Diuretics 43 (72%) 34 (81%) NS
Digoxin 10 (17%) 15 (36%) NS
Hydralazine 36 (60%) 20 (48%) NS
Statin 22 (37%) 8 (19%) NS
Aspirin 19 (32%) 10 (24%) NS
Six patients in the low testosterone group and two patients in the normal testosterone group died during the first admission. ACE-I/ARB: angiotensin-converting 
enzyme inhibitor/angiotensin receptor blocker; NS: not significant.
the association between LT and hospital readmissions, a 
critically important endpoint in this era of skyrocketing 
medical costs. The patients with HF and LT had similar 
LVEF, New York Heart Association functional class, HF 
etiology, and discharge medications, as those of patients 
with HF and NT. Interestingly, LT was accompanied by 
several markers of increased HF severity, including higher 
BNP and CRP levels, more severe renal dysfunction, 
and anemia, yet testosterone deficiency remained an 
independent predictor of readmission within 90 days of 
hospital discharge.
Figure 1 – Length of hospital stay in patients with heart failure and low testosterone (LT; n = 66) and normal testosterone (NT; n = 44). The LT group had a longer 
hospitalization stay than the NT group at the first admission. *Between group difference, p = 0.008.
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Table 3 – Single-predictor models of the Cox proportional hazard analysis for readmission within 90 days and mortality. Low testosterone 
group (n = 60) and normal testosterone group (n = 42)
Readmission within 90 days Hazard ratio 95% CI p value
Total testosterone, ng/dL 2.77 1.58-4.85 0.02
Mortality Hazard ratio 95% CI p value
Sodium, mEq/L 0.89 0.81-0.97 0.01
Total testosterone, ng/dL 4.65 2.67-8.10 0.009
Readmission - 90 days 3.27 1.23-8.69 0.02
Six patients in the low testosterone group and two patients in the normal testosterone group were excluded from the single-predictor models due to mortality during 
the first admission. CI: confidence interval.
It is unknown if a testosterone deficiency is only a 
strong marker for poor prognosis in patients with HF, or 
whether LT contributes directly to increased morbidity and 
mortality. Testosterone deficiency is associated with many 
signs and symptoms, several of which are indistinguishable 
from normal aging, including declining libido, increased 
body fat, osteoporosis, mild anemia, depression, and 
fatigue28. The most easily recognizable manifestation of 
a testosterone deficiency is a decline in muscle strength 
and bulk, which is associated with a decline in exercise 
capacity28. Exogenous testosterone improves exercise 
capacity29,30. Baseline testosterone levels were directly 
related to exercise capacity in five small, controlled trials 
of testosterone treatment in patients with HF, including 
those with LT, NT, and one trial of women with HF. 
Furthermore, 3-month testosterone therapy compared 
with placebo is associated with increased exercise capacity 
in many studies8,11-14. As hospitalization for HF is often 
prompted by increased fatigue and shortness of breath 
and the mechanisms underlying these symptoms vary31-33 
but includes progressive muscle weakness, it is tempting to 
speculate that testosterone deficiency may be an important 
contributor to the ongoing peripheral muscle decline, and 
thereby is a direct contributor to re-hospitalization risk. 
A controlled trial of testosterone therapy in patients with 
advanced HF would clarify this issue.
Figure 2 – Kaplan–Meier readmission curves within the 1-year follow-up in patients with heart failure. The low testosterone group showed more cumulative readmissions 
than the normal testosterone group within the year (p = 0.001). The 1-year follow-up started at hospital discharge (time zero).
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According to the muscle hypothesis, exercise limitations 
in patients with HF reside in the periphery, specifically 
in skeletal muscles15,16,34,35. Furthermore, skeletal muscle 
abnormalities in patients with HF may contribute to 
abnormal neurohumoral activation, including exaggerated 
increases in sympathetic nerve activity35-38. In a study of 
male rats with HF, castration was associated with changes 
in cardiac sympathetic nerve activity and increased 
plasma norepinephrine levels39. This sympatho-excitation 
was reversed by testosterone replacement therapy, as 
observed by decreased plasma norepinephrine, increased 
myocardial norepinephrine, the density of tyrosine 
hydroxylase (TH) protein-labeled nerve fibers, and 
upregulated expression of myocardial TH protein. In a 
recent study of patients with mild HF, Rydlewska et al17 
reported that testosterone deficiency is directly related to 
lower baroreceptor sensitivity and HRV. Similarly, castration 
significantly attenuates baroreceptor control of reflex 
bradycardia versus no effect on reflex tachycardia in rats. 
Testosterone replacement increases baroreflex sensitivity 
and restores reflex bradycardic responses40. In our 
study, resting MSNA was higher in patients with LT; it is 
intriguing to speculate that testosterone therapy may have 
a modulating effect on sympathetic activation in patients 
with HF, which may be mediated by ameliorating abnormal 
reflexes originating in peripheral muscles and/or potentially 
through an effect on the baroreceptors themselves.
Limitations
We recognize several limitations in our study. Androgen 
levels were only measured at one time point during the index 
admission for decompensated HF. It is not known whether 
androgen levels fluctuate in patients with HF based on their 
clinical status. All patients with HF were decompensated at 
the time testosterone levels were obtained; it is unknown 
whether testosterone provides similar important prognostic 
information in less ill patients with HF.
MSNA was recorded in 25% of the patients during 
hospitalization after they were stabilized because we could 
not conduct this procedure during acute decompensation. 
Our MSNA results are representative of only a small 
subgroup of patients; thus, the results need to be confirmed 
in a larger group.
We did not have exercise data on our patients, and peak 
VO2 is known to provide important prognostic information 
in patients with advanced HF. However, all patients were 
decompensated at the time of enrollment, and all were too 
ill to perform a CPX, which is a uniformly poor prognostic 
sign. Importantly, within this group of patients with HF 
who were too ill to provide exercise data, testosterone 
levels provided important prognostic information. 
The incidence of sleep apnea was not assessed in this 
group, which is another important risk factor that should 
be assessed in the future.
Figure 3 – Kaplan–Meier survival curves within the 1-year follow-up in patients with heart failure. The low testosterone group had a higher mortality rate than the normal 
testosterone group within the year (p = 0.001). The 1-year follow-up started at hospital discharge (time zero).
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Finally, this study was conducted at a single institution 
(Heart Institute at the University of São Paulo, Brazil) and 
we only included males with HF. It is unknown whether 
testosterone therapy would be beneficial in females with HF, 
but it is an intriguing possibility.
Conclusions
Our results support the notion that LT is an independent 
risk factor for hospital readmission within 90 days and 
increased mortality in patients with HF. Furthermore, we 
observed a possible modulating effect of LT on sympathetic 
activation in patients with HF.
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